In its debut Japan investment, L Catterton plans to help eyewear maker Owndays expand its customer-friendly business model outside its home market
HarbourVest Partners has led a secondary transaction worth approximately $420 million that enabled Capital Today China Group to take out an investment from its first fund – Yifeng Pharmacy – and roll it into a new vehicle as a means of extending the...
China’s Alphamab Oncology has completed a $100 million Series A funding round from a group of investors including PAG Growth Capital, Advantech Capital, and OrbiMed.
Hillhouse Capital and Quan Capital have led a $93 million Series B round for NextCure, a US-based biopharmaceutical company focused on cancer and other diseases.
CStone Pharmaceuticals, a cancer-focused Chinese biopharmaceutical developer with a number of PE and VC backers, has filed for an IPO in Hong Kong.
PE and VC players remain focused on Southeast Asia’s long-term growth trajectory despite gathering macro storm clouds. Valuations remain a bone of contention
Large-cap GPs are setting their sights on listed companies, with healthcare, education and technology top of the list
L Catterton Asia has made its first investment in Japan, partnering Mitsui & Co. Principal Investments (MCPI) to support local eyewear retailer Owndays.
Growth stage technology deals have retained a strong following in 2018, but elsewhere in Chinese private equity the mood is more somber
Intel Capital has led an investment of undisclosed size in Huiyi Huiying, a Chinese medical imaging technology developer that uses artificial intelligence (AI).
Asian PE appears to be entering a transitional period as an assortment of macro issues loom over the global economy. GPs anticipate an adjustment in valuations, but woe betide he who tries to call the cycle
Warburg Pincus has acquired a China healthcare business from DKSH Group, a market expansion services provider that focuses on Asia, for approximately CHF100 million ($100 million). It is the GP's first control deal in China.
China and US-based XtalPi has raised $61 million this year from investors impressed its use of quantum physics, computational chemistry, and artificial intelligence to bring greater certainty to drug development
Chinese cancer drug developer Innovent Biologics, which has a number of PE backers, closed up on its Hong Kong trading debut, following a HK$3.3 billion ($421 million) IPO.
China’s Insight Capital has reached a second close on its latest healthcare fund with commitments of RMB500 million ($71.7 million).
Vivo Capital and Orbimed have co-led an $80 million Series B funding round for US and China-based Terns Pharmaceuticals.
A healthcare fund managed by China Life Insurance has led a $46 million extended Series B investment in XtalPi, a US-based artificial intelligence-enabled healthcare services platform established by Chinese scientists.
Xgene Pharmaceutical, a Chinese drug maker, has raised $20 million in a Series B round of funding led by Ping An Ventures with participation from Zhongtai Investment – a unit of Indonesia’s Sinar Mas Group – and existing investors Morningside Venture...
KKR will take a minority stake in Australian cancer and cardiac services provider GenesisCare – just over two years since exiting the business to a consortium led by China Resources Group.
A group of private equity investors led by BGH Capital has renewed its approximately $4.1 billion ($2.9 billion) bid for Australia-listed hospital operator Healthscope. A similar offer was rejected earlier this year.
Kendall Court backs Mandaya Medical's bid to capture the demand for quality healthcare among Indonesia's growing middle class
Michael Carmen, a senior managing director and PE lead portfolio manager at Wellington Management, discusses the growing opportunity in the late-stage pre-IPO market and the challenges for investors
China Everbright has completed the first close of RMB800 million ($115.4 million) on its third healthcare fund. The overall target for the vehicle is around RMB1.5 billion.
Kendall Court has invested $55 million in Mandaya Medical, a healthcare-focused subsidiary of Indonesian conglomerate Selaras Group, via convertible preference shares.